Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization

Journal of Virology

Volumn 79, Issue 17, 2005, Pages 11547-11551

  De Swart, Rik L ^a   Yüksel, Selma ^a   Osterhaus, Albert D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; NEUTRALIZING ANTIBODY; VIRUS FUSION PROTEIN;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MEASLES VIRUS; MELANOMA CELL; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; SERUM; VACCINATION; VIRUS NEUTRALIZATION;

ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; HEMAGGLUTININS, VIRAL; HUMANS; MEASLES; MEASLES VIRUS; NETHERLANDS; NEUTRALIZATION TESTS; VIRAL FUSION PROTEINS;

MEASLES VIRUS;

EID: 23844448361     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.17.11547-11551.2005     Document Type: Article

References (16)

1. Bouche, F. B., O. T. Ertl, and C. P. Muller. 2002. Neutralizing B cell response in measles. Viral Immunol. 15:451-471.
2. Chen, R. T., L. E. Markowitz, P. Albrecht, J. A. Stewart, L. M. Mofenson, S. R. Preblud, and W. A. Orenstein. 1990. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162:1036-1042.
3. De Swart, R. L., H. W. Vos, F. G. C. M. UytdeHaag, A. D. M. E. Osterhaus, and R. S. Van Binnendijk. 1998. Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies by a FACS-measured immunofluorescence assay. J. Virol. Methods 71:35-44.
4. Duke, T., and C. S. Mgone. 2003. Measles: not just another viral exanthem. Lancet 361:763-773.
5. El Mubarak, H. S., S. A. Ibrahim, H. W. Vos, M. M. Mukhtar, O. A. Mustafa, T. F. Wild, A. D. M. E. Osterhaus, and R. L. De Swart. 2004. Measles virus protein-specific IgM, IgA and IgG subclass responses during the acute and convalescent phase of infection. J. Med. Virol. 72:290-298.
6. Garly, M.-L., and P. Aaby. 2003. The challenge of improving the efficacy of measles vaccine. Acta Trop. 85:1-17.
7. Griffin, D. E. 2001. Measles virus, p. 1401-1441. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, Pa.
8. Hartter, H. K., R. L. De Swart, F. Hanses, H. W. Vos, F. B. Bouche, A. D. M. E. Osterhaus, F. Schneider, and C. P. Muller. 2000. Evaluation of different measles IgG assays based on recombinant proteins using a panel of low-titre sera. J. Virol. Methods 84:191-200.
9. Klingele, M., H. K. Hartter, F. Adu, W. Ammerlaan, W. Ikusika, and C. P. Muller. 2000. Resistance of recent measles virus wild-type isolates to antibody-mediated neutralization by vaccinees with antibody. J. Med. Virol. 62:91-98.
10. Samb, B., P. Aaby, H. C. Whittle, A. M. Coll Seek, S. Rahman, J. Bennett, L. Markowitz, and F. Simondon. 1995. Serologie status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr. Infect. Dis. J. 14:203-209.
11. Santibanez, S., S. Niewiesk, A. Heider, J. Schneider-Schaulies, G. A. M. Berbers, A. Zimmermann, A. Halenius, A. Wolbert, I. Deitemeier, A. Tischer, and H. Hengel. 2005. Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? J. Gen. Virol. 86:365-374.
12. Stittelaar, K. J., L. S. Wyatt, R. L. De Swart, H. W. Vos, J. Groen, G. Van Amerongen, R. S. Van Binnendijk, S. Rozenblatt, B. Moss, and A. D. M. E. Osterhaus. 2000. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles vaccine in the presence of passively acquired antibodies. J. Virol. 74:4236-4243.
13. Tatsuo, H., N. Ono, K. Tanaka, and Y. Yanagi. 2000. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406:893-897.
14. Van Binnendijk, R. S., M. C. M. Poelen, G. Van Amerongen, P. De Vries, and A. D. M. E. Osterhaus. 1997. Protective immunity in macaques vaccinated with live attenuated, recombinant and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175:524-534.
15. Van den Hof, S., G. A. M. Berbers, H. E. De Melker, and M. A. E. Conyn-van Spaendonck. 1999. Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccination coverage. Vaccine 18:931-940.
16. World Health Organization. 2003. Update of the nomenclature for describing the genetic characteristics of wild-type measles viruses: new genotypes and reference strains. Wkly. Epidemiol. Rec. 78:229-232.